<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>This prospective trial assessed the safety and efficacy of allogeneic hematopoietic stem cell transplantation from a HLA-matched donor with a reduced-intensity regimen (RIST) consisting of iv fludarabine 30 mg/m(2) for 6 days and oral <z:chebi fb="0" ids="28901">busulfan</z:chebi> 4 mg/kg/day for 2 days in patients older than 50 years with <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematological malignancies</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain><z:chebi fb="0" ids="4031">Cyclosporine</z:chebi> alone or <z:chebi fb="0" ids="4031">cyclosporine</z:chebi> with short-term <z:chebi fb="0" ids="44185">methotrexate</z:chebi> was randomized for <z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">graft-versus-host disease</z:e> prophylaxis </plain></SENT>
<SENT sid="2" pm="."><plain>After 30 patients had been enrolled, an interim analysis was performed, and this report focuses on a precise evaluation of the toxicity profile and chimerism kinetics </plain></SENT>
<SENT sid="3" pm="."><plain>Sustained engraftment in <z:hpo ids='HP_0000001'>all</z:hpo> patients, no severe regimen-related toxicity (RRT) within 20 days, and no transplant-related mortality through Day 100 were observed </plain></SENT>
<SENT sid="4" pm="."><plain>T-cell (CD3+) full-donor (over 90%) chimerism was observed in 22 of the 30 patients, while the remaining eight had mixed-donor chimerism over 77% on Day 90 </plain></SENT>
<SENT sid="5" pm="."><plain>Thereafter, five subsequently converted to full-donor chimerism without donor lymphocyte infusion by day 120 (n = 4) or Day 180 (n = 1) </plain></SENT>
<SENT sid="6" pm="."><plain>Two showed persistent mixed chimerism without relapse through Day 180 </plain></SENT>
<SENT sid="7" pm="."><plain>Grade III-IV <z:hpo ids='HP_0011009'>acute</z:hpo> <z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">graft-versus-host disease</z:e> and extensive <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">graft-versus-host disease</z:e> occurred in 10% and 73%, respectively </plain></SENT>
<SENT sid="8" pm="."><plain>With a median follow-up of 1.5 years, overall survival and disease-free survival at 1 year was 83% and 62%, respectively </plain></SENT>
<SENT sid="9" pm="."><plain>Seven patients hematologically relapsed overall, and five of them had <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> with poor prognostic factors </plain></SENT>
<SENT sid="10" pm="."><plain>In older patients, RIST with fludarabine and <z:chebi fb="0" ids="28901">busulfan</z:chebi> was associated with acceptable toxicities and a satisfactory antileukemia effect, regardless of the early chimerism status </plain></SENT>
</text></document>